An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Trial Profile

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Haemolytic uraemic syndrome
  • Focus Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 05 May 2015 Results published in the Alexion Pharmaceuticals Media Release.
    • 05 May 2015 According to Alexion Pharmaceuticals media release, the data from post-hoc sub-analysis was presented at American Transplant Congress (ATC) 2015.
    • 23 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top